Dexcom Inc (NASDAQ: DXCM) kicked off on Tuesday, up 1.55% from the previous trading day, before settling in for the closing price of $65.2. Over the past 52 weeks, DXCM has traded in a range of $57.52-$93.25.
Annual sales at Healthcare sector company grew by 39.06% over the past five years. While this was happening, its average annual earnings per share was recorded 25.26%. With a float of $386.73 million, this company’s outstanding shares have now reached $392.20 million.
Dexcom Inc (DXCM) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of Dexcom Inc is 1.38%, while institutional ownership is 93.34%. The most recent insider transaction that took place on Sep 05 ’25, was worth 53,934. In this transaction Director of this company sold 667 shares at a rate of $80.86, taking the stock ownership to the 22,667 shares. Before that another transaction happened on Sep 04 ’25, when Company’s EVP, Chief HR Officer sold 1,466 for $80.00, making the entire transaction worth $117,280. This insider now owns 105,223 shares in total.
Dexcom Inc (DXCM) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported 0.45 earnings per share (EPS), higher than consensus estimate (set at 0.43) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.68 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.14% during the next five years compared to 39.06% growth over the previous five years of trading.
Dexcom Inc (NASDAQ: DXCM) Trading Performance Indicators
Take a look at Dexcom Inc’s (DXCM) current performance indicators. Last quarter, stock had a quick ratio of 1.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.04. Likewise, its price to free cash flow for the trailing twelve months is 45.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.43, a number that is poised to hit 0.57 in the next quarter and is forecasted to reach 2.58 in one year’s time.
